Ibrutinib and Eplerenone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ibrutinib (ibrutinib) and Eplerenone (eplerenone). Common drug interactions include cardiac failure among males.

The phase IV clinical study analyzes what interactions people have when they take Ibrutinib and Eplerenone. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Ibrutinib?

Ibrutinib has active ingredients of ibrutinib. eHealthMe is studying from 13,529 Ibrutinib users. Check the latest studies of Ibrutinib.

What is Eplerenone?

Eplerenone has active ingredients of eplerenone. It is often used in high blood pressure. eHealthMe is studying from 9,979 Eplerenone users. Check the latest studies of Eplerenone.

On Aug, 05, 2026

22 people who take Ibrutinib and Eplerenone together, and have interactions are studied.

Ibrutinib and Eplerenone drug interactions.

What are the common drug interactions of Ibrutinib and Eplerenone, by gender? *:

female:

n/a

male:

Cardiac failure
Tachyarrhythmia (disturbance of the heart rhythm in which the heart rate is abnormally increased)
Cardiac failure congestive
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Ventricular arrhythmia (problem with the rate or rhythm of the heartbeat)
Cardiac arrest
Dizziness
Loss of consciousness
Sinus node dysfunction (a group of abnormal heart rhythms)
Syncope (loss of consciousness with an inability to maintain postural tone)

What are the common drug interactions of Ibrutinib and Eplerenone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Cardiac failure
Tachyarrhythmia (disturbance of the heart rhythm in which the heart rate is abnormally increased)
Cardiac failure congestive
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Ventricular arrhythmia (problem with the rate or rhythm of the heartbeat)
Cardiac arrest
Dizziness
Loss of consciousness
Sinus node dysfunction (a group of abnormal heart rhythms)
Syncope (loss of consciousness with an inability to maintain postural tone)

What are the existing conditions these people have? *

Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 15 people, 68.18%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 15 people, 68.18%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 13.64%
Pneumonia: 2 people, 9.09%
Oesophagitis (inflammation of oesophagus): 2 people, 9.09%
Oedema Peripheral (superficial swelling): 2 people, 9.09%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 2 people, 9.09%
Constipation: 2 people, 9.09%
Anaemia (lack of blood): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrutinib and Eplerenone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously